Citigroup Reiterates Buy Rating on ACADIA Pharmaceuticals
Citigroup maintains its buy rating on ACADIA Pharmaceuticals with a $35 price target, a 37.28% upside from the current price.
Key Points
- Citigroup reiterated its buy rating on ACADIA Pharmaceuticals (ACAD) with a $35 price target on June 29, 2026.
- Citigroup's $35 price target implies 37.28% upside from ACADIA Pharmaceuticals Inc.'s ($ACAD) current $25.50 share price.
- ACADIA Pharmaceuticals, trading around $25.32, has a market cap of about $4.34 billion and a P/E ratio of 11.46.
- Baker Bros. Advisors LP holds 42.9 million shares, while BlackRock added 795,469 shares to its holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citigroup reiterated its buy rating on ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) on June 29, 2026. Analyst Yigal Nochomovitz maintained the rating with a price target of $35.
Citigroup vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ACADIA Pharmaceuticals Inc. Stock Down 11.8%
Shares of NasdaqGS:ACAD traded near $25.32 on Monday. ACADIA Pharmaceuticals has a market cap of approximately $4.34 billion, with a P/E ratio of 11.46 and a forward P/E of 28.68. The stock's 52-week range is between $19.69 and $28.35, and it has a 50-day moving average of $21.85 and a 200-day moving average of $23.24. The company's beta is 0.83, indicating lower volatility compared to the market.
$ACAD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in ACADIA Pharmaceuticals
Baker Bros. Advisors LP holds a significant stake in ACADIA Pharmaceuticals with 42.9 million shares valued at about $954.9 million, unchanged in the recent period. BlackRock, Inc. increased its holdings by 795,469 shares, bringing its total to 21.6 million shares worth approximately $479.7 million, a 3.8% increase. Vanguard Portfolio Management LLC opened a new position with 8.7 million shares valued at around $193 million. State Street Corp added 422,038 shares, ending with 8.3 million shares worth about $185.5 million, marking a 5.3% increase.
Recent Earnings
For its most recent quarter, ACADIA Pharmaceuticals reported revenue of $1.10 billion, reflecting a growth rate of 9.7%. The company achieved an earnings per share (EPS) of $2.21, with a net margin of 34.3% and a return on equity (ROE) of 37.3%. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at ACADIA Pharmaceuticals Inc.
On May 29, 2026, several insider transactions were reported. Baker Bros. Advisors LP made multiple purchases, including 32,008 and 37,244 shares. Jonathan Poole, James Daly, and Laura Brege also bought 16,004, 16,004, and 8,107 shares, respectively. Meanwhile, Adora Ndu sold 8,107 shares.
Analysts Set New Price Targets
On June 29, 2026, Canaccord Genuity maintained its buy rating on ACADIA Pharmaceuticals with a $36 price target. Previously, on March 25, 2026, B of A Securities upgraded the stock to a buy with a $29 target. The consensus among analysts is a buy rating, with an average target price of $32 based on 20 analyst opinions.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing and commercializing medicines for neurological and rare diseases in North America. The company is known for its product NUPLAZID, used to treat Parkinson's disease psychosis, and DAYBUE, for Rett syndrome. ACADIA is led by CEO Catherine E. Owen Adams and employs around 796 people.
Bottom Line
Citigroup's reiterated buy rating on ACADIA Pharmaceuticals, with a price target of $35, reflects continued confidence in the company's prospects. Investors closely watch these ratings as they provide insights into potential stock performance. However, it's important to remember that such analyst ratings are just one piece of the investment puzzle.
Get ACADIA Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACAD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.